Xcell Therapeutics Inc. (KOSDAQ:373110)

South Korea flag South Korea · Delayed Price · Currency is KRW
1,415.00
+64.00 (4.74%)
Mar 10, 2026, 3:30 PM KST
-65.90%
Market Cap 23.36B
Revenue (ttm) 1.36B
Net Income (ttm) -10.01B
Shares Out 17.29M
EPS (ttm) -915.30
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 47,705
Average Volume 762,264
Open 1,399.00
Previous Close 1,351.00
Day's Range 1,372.00 - 1,420.00
52-Week Range 1,301.00 - 4,530.00
Beta n/a
RSI 37.70
Earnings Date Mar 30, 2026

About Xcell Therapeutics

Xcell Therapeutics Inc. engages in the development and production of drugs for cell therapy. It offers CellCor, a serum-free chemically defined medium that is used to develop human mesenchymal stem cells. The company also offers XPorT, a platform that aims to develop optimal media from the perspective of the user using a variety of cells. In addition, it develops media for cell culture in various areas of the bioindustry such as cell therapy, gene therapy, exosomes, organoids and bioreactors. Xcell Therapeutics Inc. was founded in 2015 and is b... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2015
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 373110
Full Company Profile

Financial Performance

In 2024, Xcell Therapeutics's revenue was 1.93 billion, an increase of 72.11% compared to the previous year's 1.12 billion. Losses were -9.54 billion, 2.83% more than in 2023.

Financial Statements

News

There is no news available yet.